Scher HI - Search Results

1

A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy.

Haas GP, Scher HI. Haas GP, et al. Among authors: scher hi. Urol Oncol. 2015 Jun;33(6):269. doi: 10.1016/j.urolonc.2015.01.026. Epub 2015 Mar 26. Urol Oncol. 2015. PMID: 25817318 No abstract available.

2

Introduction: prostate cancer.

Scher HI. Scher HI. Semin Oncol. 1994 Oct;21(5):511-3. Semin Oncol. 1994. PMID: 7939744 No abstract available.

3

Immunological approaches for the treatment of prostate cancer.

Slovin SF, Kelly WK, Scher HI. Slovin SF, et al. Among authors: scher hi. Semin Urol Oncol. 1998 Feb;16(1):53-9. Semin Urol Oncol. 1998. PMID: 9508084 Review.

4

Outcome predictions for patients with metastatic prostate cancer.

Smaletz O, Scher HI. Smaletz O, et al. Among authors: scher hi. Semin Urol Oncol. 2002 May;20(2):155-63. doi: 10.1053/suro.2002.32938. Semin Urol Oncol. 2002. PMID: 12012302

5

Validation and clinical utility of prostate cancer biomarkers.

Scher HI, Morris MJ, Larson S, Heller G. Scher HI, et al. Nat Rev Clin Oncol. 2013 Apr;10(4):225-34. doi: 10.1038/nrclinonc.2013.30. Epub 2013 Mar 5. Nat Rev Clin Oncol. 2013. PMID: 23459624 Free PMC article. Review.

6

Enzalutamide in European and North American men participating in the AFFIRM trial.

Merseburger AS, Scher HI, Bellmunt J, Miller K, Mulders PF, Stenzl A, Sternberg CN, Fizazi K, Hirmand M, Franks B, Haas GP, de Bono J, de Wit R. Merseburger AS, et al. Among authors: scher hi. BJU Int. 2015 Jan;115(1):41-9. doi: 10.1111/bju.12898. Epub 2014 Oct 23. BJU Int. 2015. PMID: 25123978 Free PMC article. Clinical Trial.

7

Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.

Saad F, de Bono J, Shore N, Fizazi K, Loriot Y, Hirmand M, Franks B, Haas GP, Scher HI. Saad F, et al. Among authors: scher hi. Eur Urol. 2015 Feb;67(2):223-30. doi: 10.1016/j.eururo.2014.08.025. Epub 2014 Aug 27. Eur Urol. 2015. PMID: 25171902 Clinical Trial.

8

A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval.

Haas GP, Scher HI. Haas GP, et al. Among authors: scher hi. Urol Oncol. 2015 Mar;33(3):115. doi: 10.1016/j.urolonc.2014.12.004. Epub 2015 Jan 22. Urol Oncol. 2015. PMID: 25620153 No abstract available.

9

Biomarker development in the context of urologic cancers.

Kelloff GJ, Sigman CC, Scher HI. Kelloff GJ, et al. Among authors: scher hi. Urol Oncol. 2015 Jun;33(6):295-301. doi: 10.1016/j.urolonc.2015.01.007. Epub 2015 Mar 5. Urol Oncol. 2015. PMID: 25746942 Free PMC article. Review.

10

Enzalutamide: Development from bench to bedside.

Bambury RM, Scher HI. Bambury RM, et al. Among authors: scher hi. Urol Oncol. 2015 Jun;33(6):280-8. doi: 10.1016/j.urolonc.2014.12.017. Epub 2015 Mar 18. Urol Oncol. 2015. PMID: 25797385 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

697 results

Search Page

Filters